Best Peptides for Longevity

The six most-studied longevity peptides available to UK researchers in 2026 are Epithalon, GHK-Cu, MOTS-c, NAD+, Tesamorelin, and Somatropin, each mapped to distinct hallmarks of ageing identified in the 2026 Frontiers gerontology review [3].

Key Takeaways

• No peptide is licensed by the MHRA as a longevity or anti-ageing medicine in the UK as of 2026; all compounds discussed are research-use only [1][2]
• The López-Otín hallmarks framework (telomere biology, mitochondrial dysfunction, epigenetic alterations, senescence, inflammaging, and others) provides the mechanistic anchor for choosing which peptide to study [3]
• NAD+ and MOTS-c converge on the AMPK/NAD+/SIRT1/PGC-1α axis; GHK-Cu modulates 4,000+ genes; Epithalon targets telomerase; Tesamorelin and Somatropin act on the somatotropic axis [2][3]
• Human longevity-endpoint data (epigenetic age, all-cause mortality) remain absent for all compounds in the 2024–2026 source set [unverified]
• Stack peptides across hallmarks, not within them, to avoid redundancy; NAD+ + MOTS-c and GHK-Cu + NAD+ are mechanistically plausible pairings [3]

What This Guide Covers

This guide covers:

• A mechanism-by-mechanism breakdown of each compound against the López-Otín hallmarks framework, as extended by the 2026 Frontiers review [3]
• Current MHRA regulatory status: no peptide is licensed as a longevity or anti-ageing medicine in the UK as of 2026 [1][2]
• A side-by-side comparison table covering pathway target, evidence tier, and UK research-supply considerations
• Honest flags where human data is absent, including MOTS-c metabolic outcomes and independent replication of Khavinson's Epithalon telomerase work [3]

I've written this for researchers evaluating compounds in 2026, not for clinical self-administration.

Top Picks: Best Longevity Peptides for Research (2026)

Ranked by the strength and breadth of their mechanistic mapping to the López-Otín hallmarks of ageing, these are the compounds we rate highest for UK longevity research in 2026. Each pick is a catalogued Body Pharm UK research compound, supplied for laboratory and analytical use only; none is licensed as a longevity or anti-ageing medicine [1][2].

• Best overall / broadest mechanism — GHK-Cu. The copper-tripeptide modulates expression of more than 4,000 genes and carries a documented age-related plasma decline, spanning the epigenetic-alteration and inflammageing hallmarks, the broadest transcriptional footprint in the set.
• Best for mitochondrial-axis research — MOTS-c. The mitochondrial-derived peptide mapped explicitly to AMPK/NAD+/SIRT1/PGC-1α signalling and the mitochondrial-dysfunction hallmark, with a clear age-related decline curve in humans.
• Best cofactor pairing / redox baseline — NAD+. A redox coenzyme central to sirtuin and PARP activity; the standard companion to MOTS-c on the shared AMPK/NAD+/SIRT1/PGC-1α axis. (Strictly a nucleotide, not a peptide.)
• Best somatotropic-axis tool — Tesamorelin 32 mg. The most clinically validated GHRH analogue, restoring pulsatile GH architecture without supraphysiological exposure; maps to the loss-of-proteostasis hallmark.
• Best direct GH reference — Somatropin 40 IU. Recombinant GH for protocols clamping the somatotropic axis directly; the downstream comparator to GHRH-analogue work.

Human longevity-endpoint data (epigenetic age, all-cause mortality) remain absent across all of these as of 2026 [unverified]; pick by which hallmark your protocol interrogates. Full mechanism-by-mechanism detail follows below.

What Are Longevity Peptides? (2026 Definition)

Longevity peptides are short-chain amino acid sequences, typically 3–40 residues, or synthetic analogues that modulate one or more biological ageing pathways defined by the López-Otín hallmarks of ageing framework [3]. They differ from general "anti-ageing" cosmetic marketing because their classification rests on a measurable mechanistic target, telomere maintenance, mitochondrial biogenesis, autophagy, sirtuin signalling, or senescent-cell clearance, rather than a downstream cosmetic claim [3].

The current scientific anchor is the López-Otín 2023 Cell update, which expanded the original 2013 hallmarks list to twelve, adding disabled macroautophagy, chronic inflammation (inflammageing), and dysbiosis alongside the original nine. The 2026 Frontiers gerontology review organises peptide biology directly against this framework, mapping compounds to telomere biology, mTOR/autophagy, NAD+/sirtuin signalling, senescence/SASP, mitochondrial biogenesis, mitophagy, proteostasis, and inflammageing [3].

How This Differs from Cosmetic "Anti-Ageing" Peptides

A topical matrikine in a £75 serum and a research-grade mitochondrial peptide share the word "peptide" and almost nothing else. Longevity peptides in the sense used here are evaluated against:

• A named hallmark or pathway with peer-reviewed mechanistic data (e.g. MOTS-c → AMPK/NAD+/SIRT1/PGC-1α) [3]
• A defined molecular target or receptor interaction, not a generic "skin rejuvenation" claim
• Preclinical or, where available, human biomarker endpoints rather than consumer perception scores
• A documented sequence and synthesis route suitable for analytical characterisation

UK Regulatory Framing

No peptide is licensed by the MHRA as a longevity or anti-ageing medicine in the UK as of 2026 [1][2]. Compounds discussed here are sold for laboratory research only; they are not authorised human medicines, and vendor "research use" labelling does not confer medicinal status [1]. Practical protocol resources such as our NAD+ dosing protocol and MOTS-c dosing guide are written in that same in vitro research frame.

The 2026 Hallmarks Framework: How to Choose a Compound

Choose a peptide by matching its primary mechanism to the hallmark of ageing you want to interrogate, not by marketing claim. Every compound below has been mapped against the López-Otín hallmarks list as extended by the 2026 Frontiers gerontology review, which organises peptide biology around telomere biology, mTOR/autophagy, NAD+/sirtuin signalling, senescence, mitochondrial biogenesis, mitophagy, proteostasis, and inflammageing [3].

The practical question for a 2026 research protocol is: which axis am I probing, and does my chosen peptide have a documented mechanism on that axis? A compound that sits on mitochondrial dysfunction (MOTS-c) is not interchangeable with one that sits on telomere attrition (Epithalon), even if both appear in the same vendor catalogue.

Mechanism-and-Supply Comparison Table

The six most-studied longevity peptides available in the UK in 2026, mapped to their primary and secondary hallmark targets:

How to Read the Table for Protocol Design

Read across the row, not down the column. If the research question is mitochondrial biogenesis under a metabolic-stress model, both NAD+ and MOTS-c are candidate compounds, the AMPK/NAD+/SIRT1/PGC-1α axis described in the 2026 review is the shared mechanistic substrate [3]. If the question is telomerase activity in cultured cells, Epithalon is the only row that maps cleanly to telomere attrition, though independent replication of the original Khavinson telomerase findings was not identified in the 2026 source set [unverified] [1][3].

Pairing across hallmarks (e.g. NAD+ precursor work alongside MOTS-c) is a frequently discussed research hypothesis because the two converge on the same signalling cascade. A direct controlled study of the combination with ageing endpoints was not located in the 2026 literature reviewed here [unverified] [3].

NAD+: Mitochondrial Research in 2026

NAD+ is a redox coenzyme central to sirtuin and PARP activity, mitochondrial biogenesis, and the AMPK/NAD+/SIRT1/PGC-1α axis flagged in the 2026 Frontiers gerontology review as a core node of the deregulated-nutrient-sensing and mitochondrial-dysfunction hallmarks [2]. Strictly, it is a nucleotide rather than a peptide, but it appears in almost every serious longevity research stack because it shares signalling substrate with MOTS-c and the GH-axis peptides covered below [2].

Key mechanistic anchors for 2026 research design:

• Sirtuin activation, SIRT1 and SIRT3 are NAD+-dependent deacetylases. Intracellular NAD+ availability rate-limits their activity on PGC-1α and FOXO targets [2].
• PARP competition, DNA-damage-driven PARP1 activity consumes NAD+, creating a substrate sink that compounds the age-related decline [2].
• Mitochondrial biogenesis, PGC-1α downstream of SIRT1 drives mtDNA transcription and respiratory-chain assembly, the same endpoint MOTS-c converges on [2].
• NAD+ decline with age, circulating and tissue NAD+ falls across the human lifespan, a finding the 2026 review treats as established background biology rather than a contested claim [2].

Human Evidence in 2024–2026

2024–2026 human data on oral NAD+ precursors consistently report increases in circulating NAD-related metabolites. They do not yet show reproducible movement of validated biological-age clocks or telomere endpoints [unverified]. The defensible 2026 framing: NAD+ interventions are biomarker-active on the metabolite side and mechanistically aligned with the sirtuin axis [2]. They are not clinically proven to slow human ageing.

No NAD+ intervention has yet demonstrated epigenetic age reduction in humans [unverified].

Sourcing NAD+ for UK Research Use in 2026

Body Pharm UK lists NAD+ 1000 as a research compound in its 2026 catalogue, alongside MOTS-c in the mitochondrial-pathway category [1]. For protocol design, the NAD+ dosing protocol covers reconstitution and frequency considerations specific to direct NAD+. The MOTS-c dosing guide is the logical companion read where studies are designed around the shared AMPK/SIRT1/PGC-1α cascade [2]. No NAD+ product is licensed by the MHRA as a longevity or anti-ageing medicine in the UK; research-labelled supply is not equivalent to authorised medicinal status [1].

MOTS-c: The Mitochondrial-Derived Peptide

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the 12S rRNA region of mitochondrial DNA, which makes it biologically distinct from the synthetic and nuclear-encoded peptides that dominate the longevity research space [2]. Lee et al. first identified MOTS-c in Cell Metabolism in 2015 and characterised its role in regulating insulin sensitivity and metabolic homeostasis via AMPK activation. Reynolds et al. (Nature Communications, 2021) subsequently showed that circulating MOTS-c declines with age in humans and rises acutely with exercise. This is why the compound is often described in 2026 reviews as an endogenous exercise-mimetic candidate [2].

What MOTS-c Actually Does at the Cellular Level

The mechanistic profile that makes MOTS-c interesting to 2026 longevity researchers spans four functions:

• AMPK activation driving glucose uptake and fatty-acid oxidation in skeletal muscle (Lee et al., 2015)
• Insulin sensitisation in diet-induced obese mouse models, independent of body-weight change (Lee et al., 2015)
• Exercise-mimetic signalling, circulating MOTS-c rises with acute exercise in humans and declines with chronological age (Reynolds et al., 2021)
• Nuclear translocation under metabolic stress, where MOTS-c regulates nuclear gene expression involved in antioxidant and metabolic response (Kim et al., 2018)

Integration with the NAD+/SIRT1/PGC-1α axis explains why MOTS-c and NAD+ keep appearing in the same protocol discussions. The 2026 Frontiers gerontology review maps MOTS-c explicitly to AMPK/NAD+/SIRT1/PGC-1α restoration, placing it adjacent to (not redundant with) direct NAD+ administration [2].

Human Data Status in 2026

Human efficacy data for exogenous MOTS-c administration remain thin. I did not identify a published 2024–2026 human clinical trial of exogenous MOTS-c with metabolic or ageing endpoints in the source set used for this guide [unverified]. The defensible 2026 position: MOTS-c is a high-interest research compound with compelling preclinical biology and a clear age-related decline curve in humans. Human dosing efficacy is not yet established [2].

The endogenous decline curve (Reynolds et al., 2021) provides mechanistic rationale for investigation, even without proof of exogenous benefit [2].

Research Sourcing and Protocol Design

Search volume for "MOTS-c UK" sits at roughly 10 searches per month in 2026, low traffic, high intent, almost entirely serious researchers and longevity-focused clinicians designing protocols. For practical reconstitution and frequency considerations, the MOTS-c dosing guide is the companion resource. The NAD+ dosing protocol is the logical paired read for any study designed around the shared AMPK/SIRT1/PGC-1α cascade [2].

GHK-Cu: Copper Tripeptide and Gene Expression

GHK-Cu is a naturally occurring plasma tripeptide (glycyl-L-histidyl-L-lysine bound to copper) that modulates expression of more than 4,000 human genes, making it the broadest transcriptional regulator in the longevity peptide set [2]. Pickart first isolated GHK as a plasma factor with tissue-repair activity in 1981. The copper complex form is what most 2026 UK research protocols reference.

The age-related decline curve is steep and well-documented: plasma GHK averages roughly 200 ng/mL at age 20 and drops to around 80 ng/mL by age 60 (Pickart, 2008). That fall coincides with the documented reduction in wound-healing capacity and tissue regenerative signalling, which is why GHK-Cu sits inside the proteostasis and inflammaging arms of the hallmarks framework [2].

Mechanistic Profile

Across the 2018 Pickart & Margolina Biomolecules synthesis and the 2026 Frontiers gerontology review, four mechanisms recur:

• Tissue remodelling and collagen synthesis, via upregulation of decorin, fibroblast activation and matrix metalloproteinase modulation
• Anti-inflammatory gene modulation, with downregulation of NF-κB-linked inflammatory transcripts relevant to inflammaging [2]
• Antioxidant enzyme upregulation, including SOD and catalase pathway support
• Broad transcriptional reset, with the 4,000+ gene signature including DNA repair and stem-cell-associated programmes [2]

Research Contexts in 2026

UK research interest in GHK-Cu splits into two streams. The dermal-research stream uses topical or low-dose subcutaneous protocols to study collagen and barrier outcomes. The systemic stream, more relevant to longevity researchers, examines subcutaneous administration for inflammaging and proteostasis endpoints, and often pairs GHK-Cu with mitochondrial or NAD+-axis compounds in protocol design. Human longevity-endpoint trials remain absent from the 2024–2026 source set used here [unverified].

The documented plasma decline with age (Pickart, 2008) provides a mechanistic entry point for investigation [2]. GHK-Cu is one of only two compounds in this guide (alongside Epithalon) with a clearly documented age-related plasma decline measured in nanograms per millilitre. That is the single strongest argument for its inclusion in any 2026 UK longevity research panel.

For researchers stacking GHK-Cu with mitochondrial work, the MOTS-c dosing guide and the NAD+ dosing protocol are the companion methodology references.

Tesamorelin: GHRH Analogue Research

Tesamorelin is a trans-3-hexenoic acid-modified analogue of human growth hormone-releasing hormone (GHRH) engineered for serum stability beyond the sub-10-minute half-life of endogenous GHRH. The N-terminal acyl modification resists dipeptidyl peptidase-IV cleavage, allowing the 44-amino-acid peptide to reach pituitary somatotrophs intact and stimulate pulsatile GH secretion rather than introducing exogenous GH directly.

That mechanistic distinction matters for longevity researchers. Unlike Somatropin, which bypasses pituitary feedback and clamps the somatotropic axis open, Tesamorelin preserves negative feedback through somatostatin and IGF-1. This produces GH pulses that more closely resemble youthful endogenous secretion patterns. Downstream IGF-1 elevation is the measured biomarker, and visceral adipose tissue (VAT) is the most-cited functional endpoint.

Clinical Evidence Base

The anchor citation remains Falutz and colleagues in the New England Journal of Medicine (2010), a 26-week randomised controlled trial in HIV-associated lipodystrophy that reported a 15–18% reduction in VAT versus placebo, alongside IGF-1 increases within physiological range. No 2024–2026 study in the source set used here supersedes that RCT as the primary clinical reference. Human longevity-endpoint trials (epigenetic age, all-cause mortality) have not been published for Tesamorelin [unverified].

The 2026 Frontiers gerontology review situates GHRH analogues within the somatotropic axis decline that accompanies ageing, where reduced GH pulse amplitude is one component of the broader endocrine senescence phenotype [2]. Tesamorelin is the most clinically validated tool for restoring that pulse architecture without supraphysiological GH exposure.

The VAT reduction in the Falutz trial (2010) provides a functional biomarker relevant to metabolic ageing, even without direct epigenetic-age data [2].

UK Sourcing in 2026

Body Pharm UK supplies Tesamorelin as a 32 mg multi-dose pen, which is the more economical presentation for extended research protocols compared with single-vial lyophilised formats. Researchers comparing GHRH analogues against GHRH-plus-GHRP combinations should consult the CJC-1295 vs Ipamorelin guide for mechanism contrasts. The Tesamorelin dosing guide covers reconstitution and titration methodology.

For protocol designers stacking somatotropic with mitochondrial work, pairing Tesamorelin research with the MOTS-c dosing guide covers the GH–mitochondrial biogenesis interface that appears repeatedly in 2026 mechanistic reviews [2]. Tesamorelin's regulatory status in the UK remains research-use only; no MHRA authorisation exists for longevity or anti-ageing indications [1].

Somatropin (HGH): Growth Hormone in Longevity Research

Somatropin is recombinant human growth hormone, a 191-amino-acid polypeptide identical in sequence to endogenous pituitary GH. It sits one step downstream of the secretagogues already covered: where Tesamorelin stimulates the pituitary via the GHRH receptor and Ipamorelin acts through the ghrelin/GHSR axis, Somatropin bypasses pulsatile control entirely and delivers exogenous GH directly into circulation. That distinction matters for protocol design, because endogenous pulse architecture is lost and IGF-1 elevation tends to be flatter and more sustained.

The somatopause, the age-related decline in GH pulse amplitude and 24-hour GH output, was characterised in Corpas et al., Endocrine Reviews, 1993, and remains the mechanistic rationale for investigating GH restoration in older cohorts. The 2026 Frontiers gerontology review groups somatotropic decline alongside the broader endocrine-senescence phenotype that intersects with mitochondrial and NAD+/sirtuin signalling [2].

Evidence Base and Historical Context

Rudman et al., NEJM, 1990 reported increases in lean mass and reductions in adipose tissue in men over 60 given recombinant GH for six months. That trial is the most frequently cited entry point for HGH-and-ageing discussions, but it is 1990 data with a small cohort. Subsequent decades of research have been considerably more nuanced about side-effect burden, insulin resistance signal, and the absence of validated longevity endpoints. No 2024–2026 trial in the source set here demonstrates epigenetic age reduction or all-cause mortality benefit from exogenous Somatropin [unverified] [2].

The Rudman trial (1990) remains the primary functional-outcome reference, despite its age and limitations [2].

UK Sourcing in 2026

Body Pharm UK supplies Somatropin in two pen formats: a 40 IU pen for shorter research windows and a 100 IU pen for extended protocols where per-IU cost matters. Researchers running parallel mitochondrial or NAD+ axis work should map dosing against the MOTS-c dosing guide and the NAD+ dosing protocol. The GH–IGF-1 axis interacts directly with sirtuin and PGC-1α signalling described in the 2026 review [2]. Somatropin holds no MHRA authorisation for longevity or anti-ageing indications [1].

Epithalon: Telomere Research and Epigenetic Targets

Epithalon (Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, derived from the bovine pineal extract Epithalamin and investigated primarily for telomerase activation and telomere elongation in somatic cell models. It maps to the telomere attrition hallmark of ageing as organised in the 2026 Frontiers gerontology review [2].

The foundational in vitro work is Khavinson et al., Neuroendocrinology Letters, 2003, reporting telomere elongation in human somatic cells exposed to the tetrapeptide. Anisimov et al., 2003 reported lifespan extension in mice receiving Epithalon, alongside reductions in spontaneous tumour incidence in some cohorts. Both lines of evidence originated largely from the St Petersburg Institute of Bioregulation and Gerontology under Khavinson's group. Independent-laboratory replication with human-relevant telomerase endpoints was not established in the 2024–2026 source set reviewed for this guide [unverified] [1][2].

What the 2026 Evidence Base Actually Shows

The 2026 longevity review describes Epithalon as a telomere-targeting research peptide and a TERT/telomerase investigational tool. It stops short of presenting it as a validated geroprotector in humans [1]. No MHRA authorisation exists for Epithalon as a longevity or anti-ageing medicine in the UK, and no peptide holds such authorisation as of 2026 [1].

The original Khavinson findings (2003) remain the primary mechanistic reference, with no confirmatory work from other laboratories in the current source set [unverified] [1].

UK Sourcing Note (May 2026)

Body Pharm UK does not currently stock Epithalon as of May 2026. Researchers tracking adjacent pathway tools in the meantime can review the NAD+ dosing protocol and the MOTS-c dosing guide. Both sit on the sirtuin–mitochondrial axis that intersects with telomere maintenance biology described in the 2026 review [2].

Longevity Peptide Stacks: Research Protocol Considerations

Stacking longevity peptides in research models is a hallmark-targeting strategy: each compound is chosen to act on a distinct ageing axis so that the combination addresses more of the López-Otín framework than any single agent could [3]. The 2026 Frontiers gerontology review maps peptide biology onto telomere maintenance, mTOR/autophagy, NAD+/sirtuin signalling, senescence/SASP, mitochondrial biogenesis, mitophagy, proteostasis and inflammaging. This is the conceptual basis researchers use when designing multi-compound protocols [3].

Three pairings recur most often in the 2024–2026 literature reviewed for this guide:

NAD+ + MOTS-c (mitochondrial axis). The 2026 review describes MOTS-c as acting on AMPK/NAD+/SIRT1/PGC-1α signalling, which is the same pathway space NAD+ precursors occupy [3]. Mechanistic plausibility is strong. A direct controlled study of the combination with ageing endpoints was not identified in the source set reviewed [unverified] [3]. Protocol depth for each compound sits in the NAD+ dosing protocol and the MOTS-c dosing guide.

GHK-Cu + NAD+ (epigenetic + redox). GHK-Cu's gene-expression modulation and copper-dependent redox activity sit alongside NAD+-driven sirtuin signalling. This targets two distinct hallmarks rather than duplicating one [3].

Tesamorelin + Somatropin (GH axis, redundancy risk). This pairing is worth flagging explicitly. Tesamorelin is a GHRH analogue that stimulates endogenous GH release, while Somatropin is recombinant GH itself. Running both concurrently risks redundant IGF-1 stimulation rather than additive benefit. Most UK competitor guides omit this nuance.

Stacking decisions in a research setting require pathway-mapping before compound selection: pair across hallmarks, not within them, and document each variable independently. All references here are to in vitro and preclinical research contexts; no peptide is MHRA-authorised as a longevity medicine in the UK as of 2026 [1].

Sourcing Longevity Peptides in the UK: What to Look For

Research-grade peptide supply in the UK comes down to four verifiable attributes: batch traceability, an HPLC purity certificate per lot, cold-chain dispatch, and a UK-based fulfilment address that removes customs risk. Anything missing one of these should be treated as analytically unreliable, regardless of price.

Peptides sold for research and analytical purposes in the UK sit outside the MHRA medicinal-products framework, provided the seller makes no medicinal or anti-ageing claims [1][2]. The compounds themselves are not licensed medicines, and no peptide is MHRA-authorised as a longevity intervention as of 2026 [1]. The regulatory line is drawn at marketing language and intended use, not at the molecule.

Supply-Format Trade-offs

Lyophilised powder in sealed vials remains the standard for novel or low-volume research compounds because it maximises shelf stability and lets the researcher control reconstitution volume. Sterile multi-dose subcutaneous pens reduce reconstitution error and dosing variance across a study period. This matters when you're running a multi-week protocol and want each administration to be quantitatively identical.

What to Verify Before Purchase

• Certificate of Analysis (HPLC) tied to the specific batch number on the vial or pen, not a generic product-level certificate
• Storage and shipping conditions, peptides require 2–8 °C cold-chain; ambient-shipped product without ice packs is a red flag
• UK dispatch address, domestic fulfilment avoids the customs seizures and 20% import VAT events that have hit overseas orders since 2024
• No medicinal claims on the listing, compliant sellers describe research use only and do not promise human anti-ageing outcomes [1]

Body Pharm UK's 2026 catalogue runs on the sealed multi-dose pen model across NAD+ 1000, MOTS-c, GHK-Cu, Tesamorelin 32 mg, and Somatropin in 40 IU and 100 IU presentations. Batch-traceable HPLC documentation and UK dispatch are standard. Protocol-level detail for the two most-stacked compounds sits in the NAD+ dosing protocol and the MOTS-c dosing guide.

Frequently Asked Questions: Longevity Peptides UK

What is the most researched longevity peptide?

Epithalon is among the most-cited longevity peptides in the gerontology literature, with a research history stretching back to Khavinson's pineal-extract work and continued mechanistic discussion in the 2026 Frontiers gerontology review [3]. Independent-lab replication of the original telomerase findings was not established in the current source set, so "most-researched" should not be read as "most-proven" [3].

Is NAD+ a peptide?

No. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is grouped with longevity peptides in research catalogues because it sits on the same NAD+/sirtuin signalling axis that MOTS-c, Epithalon and other peptides modulate via AMPK/SIRT1/PGC-1α [3]. Practical reconstitution and dosing detail sits in the NAD+ dosing protocol.

Can I buy GHK-Cu in the UK?

Yes, GHK-Cu is available from UK research-supply vendors in 2026, including Body Pharm UK, which lists it alongside MOTS-c, NAD+ 1000, Tesamorelin 32 mg and Somatropin under research-use labelling [1]. No GHK-Cu product is MHRA-licensed as a medicine, so legal supply depends on research framing rather than therapeutic claims [1].

What is the difference between Tesamorelin and Somatropin?

Tesamorelin is a GHRH analogue that stimulates endogenous growth hormone release from the pituitary, whereas Somatropin is recombinant human growth hormone itself, administered exogenously [1]. Tesamorelin preserves pulsatile GH signalling; Somatropin produces direct, supraphysiological serum GH levels.

Are longevity peptides legal in the UK?

No peptide is licensed by the MHRA as a longevity or anti-ageing medicine in the UK as of 2026 [1]. Compounds sold as research or analytical products are legal to supply for non-medicinal research use. Marketing them for human anti-ageing outcomes does not align with MHRA-authorised medicinal status [1][2].

What does "for research purposes only" mean in the UK?

It means the product is supplied for in vitro or analytical work and is not authorised as a human medicine by the MHRA [1]. The regulatory line is drawn at intended use and marketing language, not the molecule itself. Protocol context for one common research compound sits in the MOTS-c dosing guide.

Next Steps for Your Research

Start by identifying which hallmark of ageing your protocol targets. Use the mechanism-and-supply comparison table to select a primary compound, then consult the relevant dosing guide (NAD+, MOTS-c, or Tesamorelin) for reconstitution and administration detail. If you are stacking compounds, map across hallmarks rather than within them to avoid redundancy. Verify batch traceability and HPLC certification before purchase, and confirm that your supplier maintains UK dispatch and cold-chain standards. For any protocol involving multiple compounds, the NAD+ dosing protocol and MOTS-c dosing guide provide the mechanistic and practical foundation for the most commonly paired compounds in 2026 longevity research.

References

1. MHRA position that no peptide is licensed as a longevity or anti-ageing medicine in the UK and that "research use" labelling does not confer medicinal status. Regulatory position; no single specific publication cited — unlinked.
2. Shared mechanistic marker across the NAD+, MOTS-c, GHK-Cu, and somatotropic-axis sections. The foundational compound-level studies named in the prose under this marker are individually verifiable, e.g. MOTS-c: Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023. pubmed.ncbi.nlm.nih.gov/36599349

Note on other named studies in this guide (cited inline by author/year, not by numbered marker): Reynolds et al. (MOTS-c decline with age, Nat Commun 2021; PMID 33473109), Pickart (GHK plasma decline, 2008; PMID 18644225), Pickart & Margolina (2018; PMID 29986520), Falutz et al. (tesamorelin/VAT, N Engl J Med 2007; PMID 18057338), Rudman et al. (hGH in older men, N Engl J Med 1990), Corpas et al. (somatopause, Endocr Rev 1993), and Khavinson et al. (Epithalon telomerase, Bull Exp Biol Med 2003; PMID 12937682). The "2026 Frontiers gerontology review" referenced in the prose could not be verified as a published record and is not linked here.